NASDAQ:IMA ImageneBio (IMA) Stock Price, News & Analysis $14.04 0.00 (0.00%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ImageneBio Stock (NASDAQ:IMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ImageneBio alerts:Sign Up Key Stats Today's Range$14.04▼$14.1050-Day Range$14.04▼$17.9052-Week Range$11.65▼$23.28Volume2,307 shsAverage Volume13,784 shsMarket Capitalization$56.44 millionP/E RatioN/ADividend YieldN/APrice Target$35.50Consensus RatingModerate Buy Company Overview ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California. Read More ImageneBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreIMA MarketRank™: ImageneBio scored higher than 50% of companies evaluated by MarketBeat, and ranked 563rd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingImageneBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageImageneBio has only been the subject of 1 research reports in the past 90 days.Read more about ImageneBio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ImageneBio are expected to grow in the coming year, from ($0.91) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImageneBio is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImageneBio is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImageneBio has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for IMA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImageneBio does not currently pay a dividend.Dividend GrowthImageneBio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for IMA. News and Social Media0.6 / 5News SentimentN/A Search Interest9 people have searched for IMA on MarketBeat in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, ImageneBio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,499,893.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.94% of the stock of ImageneBio is held by insiders.Percentage Held by Institutions75.00% of the stock of ImageneBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ImageneBio's insider trading history. Receive IMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImageneBio and its competitors with MarketBeat's FREE daily newsletter. Email Address IMA Stock News HeadlinesIkena Oncology, Inc. (NASDAQ:IMA) Director Purchases $2,499,968.90 in StockJuly 31, 2025 | insidertrades.comImageneBio (IMA) Expected to Announce Earnings on ThursdayAugust 12, 2025 | americanbankingnews.comWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.August 20 at 2:00 AM | Priority Gold (Ad)ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comIkena Oncology Inc trading halted, news pendingJuly 26, 2025 | msn.comInmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 MillionJuly 25, 2025 | globenewswire.comIkena Oncology shares climb as Kristin Yarema named CEO of soon-to-merge ImageneBioJuly 24, 2025 | msn.comIkena Oncology stock rises after naming Kristin Yarema as CEO of combined companyJuly 24, 2025 | investing.comSee More Headlines IMA Stock Analysis - Frequently Asked Questions How have IMA shares performed this year? ImageneBio's stock was trading at $19.68 on January 1st, 2025. Since then, IMA stock has decreased by 28.7% and is now trading at $14.04. How were ImageneBio's earnings last quarter? ImageneBio, Inc. (NASDAQ:IMA) announced its quarterly earnings data on Thursday, July, 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.08. When did ImageneBio's stock split? ImageneBio shares reverse split on the morning of Monday, July 28th 2025.The 1-12 reverse split was announced on Friday, July 25th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of ImageneBio? Shares of IMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/24/2025Today8/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMA Previous SymbolNASDAQ:IMA CIK1835579 Webikenaoncology.com Phone857-273-8343FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Price Target for ImageneBio$35.50 High Price Target$48.00 Low Price Target$23.00 Potential Upside/Downside+152.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($7.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.23 million Net MarginsN/A Pretax MarginN/A Return on Equity-23.94% Return on Assets-21.62% Debt Debt-to-Equity RatioN/A Current Ratio13.52 Quick Ratio13.52 Sales & Book Value Annual Sales$9.16 million Price / Sales6.16 Cash FlowN/A Price / Cash FlowN/A Book Value$28.83 per share Price / Book0.49Miscellaneous Outstanding Shares4,020,000Free Float3,781,000Market Cap$56.44 million OptionableNot Optionable Beta0.51 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:IMA) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImageneBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImageneBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.